AlphAIAlphAI — Financial news for AI agents
ibtimes.com.auSEP 242 min read

CareDx Shares Jump 7.96% as BTIG Raises Price Target to $74 From $60 on Transplant Diagnostics Growth

CareDx Inc. shares rose 7.96% to $58.64 after BTIG raised its price target to $74 from $60, citing growth confidence. The firm has increased its target by 64% over seven weeks. CareDx focuses on transplant diagnostics and recently published clinical data supporting its AlloSure Kidney test. The company also completed acquisitions and faced mixed analyst views.

Original reporting
ibtimes.com.au
Published Sep 24, 2026, 3:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 4:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CareDx Shares Jump 7.96% as BTIG Raises Price Target to $74 From $60 on Transplant Diagnostics Growth — source image
Source · ibtimes.com.au
Decision brief

The 30-second read

Med
01

Why it matters

The BTIG price‑target hike reflects growing confidence in CareDx's growth trajectory, potentially spurring further analyst upgrades.

02

Market read

Analyst upgrade drives short‑term price action; may influence peer valuations in the diagnostics space.

03

What to watch

Recent insider sales and potential CMS reimbursement uncertainties could temper upside.

Relevance 7/10Novelty 7/10Timing: intraday today

Background

CareDx is a precision‑medicine diagnostics firm focused on transplant monitoring, recently completing acquisitions and divestitures.

Market effects

Sector

Positive signal for the transplant diagnostics and broader precision‑medicine sector.

Regional

Limited to U.S. biotech equities; no broader regional effect.

Global

Minor global relevance, primarily U.S. investors.

Counterpoint

What could challenge this read

Valuation concerns remain; the stock may be overbought relative to fair value estimates.

Key entities

  • Company
    CareDx Inc.

    Transplant diagnostics company (NASDAQ: CRDX).

  • Analyst Firm
    BTIG

    Raised CareDx price target to $74.

Read at source← All news

Related articles

SEP 25
$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min
SEP 25
$CDNAMed

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

CareDx (CDNA) shares rose 13% to $61.37 on high volume, following a price target increase to $74 by BTIG. Q2 2026 revenue grew 52% YoY, with testing services up 61%. Q3 earnings are expected at $0.24 per share, down 14.3% YoY, and revenue at $122.35M, up 22.3% YoY. The stock has a Zacks Rank of #2 (Buy). Charles River Laboratories (CRL), another medical services company, closed up 6.2% at $294.44, with a Zacks Rank of #2 (Buy).

finance.yahoo.com2 min
AUG 1
$CDNAMedAI 8/10

CareDx Q2 Earnings Call Highlights

CareDx (NASDAQ:CDNA) provided Q2 earnings call guidance. Full-year testing volume is forecast at 258,000 to 266,000 tests and testing-services revenue around $400 million, including $24 million specialty oncology. Patient and digital revenue is expected at $72 million, lab products $23 million, and non-GAAP gross margin 71% to 73%. The company also discussed Medicare LCD coverage, Q3 and Q4 test assumptions, and pipeline updates for AlloHeme and HistoMap.

yahoo.com6 min